Names Wei Te Feng to Board of Directors

Mr. Te Feng, a private investor, served as Chief Executive Officer of an asset management company based in Hong Kong with approximately $9 billion in assets

Online PR News – 06-November-2015 – Taipei –, a global biotechnology pioneer in the discovery, development, manufacturing and commercialization of innovative therapies for Alzheimer’s disease, today announced the appointment of Wei Te Feng to its Board of Directors, increasing the Board to 13 members.

"Wei Te Feng adds enormous Wall Street experience to our Board," said Steven Hsien, Chairman of Braincure Biotech. “With his professional investor's perspective, he can make important contributions to Braincure Biotech as we look forward to continuing to deliver strong performance and generate value for our stockholders.”

Mr. Te Feng holds an undergraduate degree in medicine from New York University and an M.B.A. in finance from the University Of Hong Kong School Of Business.

Upon the naming of Mr. Te Feng Braincure Biotech stockholders elected the company's Board Nominees. based on a preliminary count provided by its proxy solicitor, stockholders have elected all four of the Company’s nominees – Lin Chi Jui, Ph.D., Chao Shin, J.D., Tsai Jye, Ph.D., and Wang Hsiung, Ph.D. – to the Braincure Biotech Board of Directors at today’s Annual Meeting of Stockholders. In addition, based on that preliminary count, the proposal to amend the Company’s bylaws to set the size of the Board at 12 has been defeated. The preliminary count is subject to the official tabulation of vote results, which will be provided by Braincure Biotech’s independent inspector of elections.

Mr. Hsien said, “We are gratified that our nominees will serve on the Braincure Biotech Board of Directors. We look forward to turning our undivided attention to delivering strong performance and growing our business for stockholders.”

About Braincure Biotech is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.

visit our website